

Amendments to the Specification:

Please amend Paragraph No. [0100] on page 41 as follows:

[0100] In the methods of the present invention, the polypeptides may be administered separately or together with one or more other compounds and compositions that exhibit a long term or short-term action to reduce nutrient availability, including, but not limited to other compounds and compositions that comprise an amylin or amylin analog agonist, salmon calcitonin, a cholecystokinin (CCK) or CCK agonist, a leptin (OB protein) or leptin agonist, an exendin or exendin analog agonist, a GLP-1 or GLP-1 analog agonist, a DPPIV inhibitor, a PYY or PYY analog, AFP-6 (intermedin) or AFP-6 agonist, Urocortin or Urocortin agonist, or Adrenomedullin or Adrenomedullin agonist. Suitable amylin agonists include, for example, [25,28,29 Pro-]-human amylin (also known as "pramlintide," and described in U.S. Pat. Nos. 5,686,511 and 5,998,367). The CCK used is preferably CCK octopeptide (CCK-8). Leptin is discussed in, for example, (Pellemounter, Cullen et al., Science 269: 540-543 (1995); Halaas, Gajiwala et al., Science 269: 543-6 (1995); Campfield, Smith et al., Science 269: 546-549 (1995)). Suitable exendins include exendin-3 and exendin-4, and exendin agonist compounds include, for example, those described in PCT Publications WO 99/07404, WO 99/25727, and WO 99/25728. Suitable PYY polypeptides and analogs include those described in U.S. Application Nos.: 60/543,406 and 60/543,407 [~~Attorney Docket Nos. 18528.662 and 18528.663~~].

Please amend Paragraph No. [0130] on page 52 as follows:

[0130] In the methods of the present invention, the polypeptides may be administered separately or together with one or more other compounds and compositions that exhibit a long term or short-term action to reduce nutrient availability, including, but not limited to other compounds and compositions that comprise an amylin or amylin analog agonist, salmon calcitonin or salmon calcitonin agonist, a cholecystokinin (CCK) or CCK agonist, a leptin (OB protein) or leptin agonist, an exendin or exendin analog agonist, or a GLP-1 or GLP-1 analog agonist or a PYY or PYY analog, or a PYY related polypeptide. Suitable amylin agonists include, for example, [25,28,29 Pro-]-human amylin (also known as "pramlintide," and described in U.S. Pat.

Nos. 5,686,511 and 5,998,367). The CCK used is preferably CCK octopeptide (CCK-8). Leptin is discussed in, for example, (Pelleymounter, Cullen et al., Science 269: 540-543 (1995); Halaas, Gajiwala et al., Science 269: 543-6 (1995); Campfield, Smith et al., Science 269: 546-549 (1995)). Suitable exendins include exendin-3 and exendin-4, and exendin agonist compounds include, for example, those described in PCT Publications WO 99/07404, WO 99/25727, and WO 99/25728. Suitable PYY polypeptides and analogs include those described in U.S. Application Nos.: 11/055,093 and 11/055,098 [~~Attorney Docket Nos. 18528.740 and 18528.723~~].